Phase III Study of ASP2151 in Herpes Zoster Patients

PHASE3CompletedINTERVENTIONAL

Enrollment

751

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

July 10, 2015

Conditions

Herpes Zoster

Interventions

DRUG

ASP2151

200 mg once daily or 400 mg once daily

DRUG

valaciclovir

1000 mg three times daily

Trial Locations (3)

Sapporo

Yokohama

Nakano-Ku

All Listed Sponsors

lead

Maruho Co., Ltd.

INDUSTRY

NCT01959841 - Phase III Study of ASP2151 in Herpes Zoster Patients | Biotech Hunter | Biotech Hunter